Images List Premium Download Classic

Psychiatric Disorders

Psychiatric Disorders-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors
Merck Sharp & Dohme Corp.
June 14, 2018 - N°20180162874

The present invention is directed to pyrimidine carboxamide compounds of formula i which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (pde2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, parkinson's disease, parkinson's disease dementia (pdd), or huntington's disease, ...
Pyridine and pyrimidine derivatives
June 14, 2018 - N°20180162824

The compounds of formula i may be used in the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.. .
Heterocyclic compounds for the treatment of neurological and psychological disorders
Alkermes Pharma Ireland Limited
June 14, 2018 - N°20180162816

Lactam compounds of formula i and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed.. .
Psychiatric Disorders Patent Pack
Download + patent application PDFs
Psychiatric Disorders Patent Applications
Download + Psychiatric Disorders-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Psychiatric Disorders-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Dihydropyrazolopyrimidinone compounds as pde2 inhibitors
Msd R & D (china) Co. Ltd.
May 31, 2018 - N°20180148453

The present invention is directed to dihydropyrazolopyrimidinone compounds of formula (i) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (pde2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, parkinson's disease, parkinson's disease dementia (pdd), or huntington's disease, and ...
Bicyclic heterocyclic compounds as pde2 inhibitors
Merck Sharp & Dohme Corp.
May 24, 2018 - N°20180141952

The present invention is directed to dihydropyrazolopyrimidinone compounds of formulas (i) and (ii) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (pde2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, parkinson's disease, parkinson's disease dementia (pdd), or huntington's ...
Treatment or prophylaxis of a neurological or neuropsychiatric disorders via ocular administration
Phovitreal Pty Ltd
May 24, 2018 - N°20180140561

A method for the treatment and/or prophylaxis of a neurological and/or neuropsychiatric disorder associated with altered dopamine function comprising administering to the eye of a patient in need thereof an effective amount of an agent that modulates neurotransmitter production or function.. .
Psychiatric Disorders Patent Pack
Download + patent application PDFs
Psychiatric Disorders Patent Applications
Download + Psychiatric Disorders-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Psychiatric Disorders-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Ligands selective to alpha 6 subunit-containing gabaa receptors and their methods of use
University Of Belgrade - Faculty Of Pharmacy
May 17, 2018 - N°20180134698

Provided herein are novel pyrazolo-quinolinone compounds and method of using such compounds to treat disorders such as neuropsychiatric disorders with sensorimotor gating deficits, such as schizophrenia, tic disorders, attention deficit hyperactivity disorder, obsessive compulsive disorder, panic disorder, huntington's disease and nocturnal enuresis;depression; temporomandibular myofascial pain; disorders of trigeminal nerve, such as trigeminal neuralgia and trigeminal neuropathy; migraine; and tinnitus.. .
Pupil distortion measurement and psychiatric diagnosis method
May 17, 2018 - N°20180132775

A prediction, diagnosis, or suggesting of a diagnosis of a psychiatric disorder is made based in embodiments of the disclosed technology by determining a shape of one or both pupils in an image of a patient. Such a diagnosis can be made in real-time by diagnosing the patient, or by viewing a digitized version of the patient's face as part ...
Imidazole derivatives
May 10, 2018 - N°20180125823

The compounds of formula i may be used in the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.. .
Substituted imidazopyridine and triazolopyridine analogs as positive allosteric modulators of muscarinic acetylcholine receptor m1
Vanderbilt University
May 03, 2018 - N°20180118746

In one aspect, the invention relates to substituted imidazopyridine and triazolopyridine analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor m1 (machr m1); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the disclosed ...
Imidazole derivatives
May 03, 2018 - N°20180118692

Or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof for use in the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.. .
(r)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2...
Bristol-myers Squibb Company
April 19, 2018 - N°20180104265

The disclosure generally relates to compounds of formula i, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nr2b nmda receptor and may be useful for the treatment of various disorders of the central nervous system..
1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
April 05, 2018 - N°20180093974

And pharmaceutically acceptable salts thereof, wherein a, ra, r1, r2, r3, r4, r6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein..
Psychiatric Disorders Patent Pack
Download + patent application PDFs
Psychiatric Disorders Patent Applications
Download + Psychiatric Disorders-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Psychiatric Disorders-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Positive allosteric modulators of the muscarinic acetylcholine receptor m4
Vanderbilt University
March 29, 2018 - N°20180086776

Disclosed herein are substituted 8-aminothieno[3,2-e][1,2,4]triazolo[4,3-b]pyridazine-7-carboxamide compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor m4 (machr m4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions..
Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
Axovant Sciences Gmbh
March 29, 2018 - N°20180085367

The combination of 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline or a pharmaceutically acceptable salt thereof with a second therapeutic agent, and its use for the treatment of a) psychiatric disorders with prominent cognitive deficits e.g. Chronic ptsd (post traumatic stress disorder); b) non-degenerative disorders with prominent cognitive deficits e.g.
Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
Auspex Pharmaceuticals, Inc.
March 29, 2018 - N°20180085327

Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar ...
5ht3 receptor antagonists
March 15, 2018 - N°20180072758

That are 5-ht3 receptor antagonists and are therefore useful for the treatment of diseases treatable by inhibition of 5-ht3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric disorders, and gi disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds..
Selective fkbp51 ligands for treatment of psychiatric disorders
Max-planck-gesellschaft Zur Förderung Der Wissenschaften E.v.
March 15, 2018 - N°20180072667

The present invention relates to compounds having a selective fkbp51 ligand scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said selective fkbp51 ligand compounds can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions..
Diphenethylamine derivatives which are inter alia useful as analgesics and method for their production
University Of Innsbruck
March 15, 2018 - N°20180072654

Diphenethylamine derivatives for use as highly active analgesics, diuretics, anxiolytics, for the treatment of neurode-generative, psychiatric and neuropsychiatric disorders, and also as anti-itch, anti-addiction, anti-inflammatory, anti-obesity, anti-epileptic, anti-convulsant, anti-seizure, anti-stress, anti-psychotic and anti-depressant medications and their pharmaceutically acceptable salts and easily accessible derivatives thereof (e.g. Esters, ethers, amides), processes for their preparation and their application in the manufacture of ...
Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders
March 01, 2018 - N°20180057506

And pharmaceutically acceptable salts thereof, wherein ring b, a1, a2, r6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein..
Isoquinoline amide and isoquinoline amide-substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating ...
Vanderbilt University
March 01, 2018 - N°20180057491

Compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mglur4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.. .
Loading